Oncotect
Oncotect is a Raleigh-based biotech startup pioneering the world's first at-home, non-invasive cancer screening test for dogs. The test requires only 2 mL of urine to screen for the four most common treatable canine cancers: melanoma, lymphoma, mast cell tumor, and hemangiosarcoma, with a reported accuracy of 90% (83% true positive and 96% true negative). The business model is direct-to-consumer with options for veterinary professional use, offering affordable pricing to make regular screening accessible. They have served over 200 veterinarians and thousands of dog parents, aiming to provide peace of mind and increase treatment options by enabling early cancer detection in dogs. Oncotect is positioned as a routine preventative care measure, recommended annually or every six months for high-risk breeds.
Oncotect
Oncotect is a Raleigh-based biotech startup pioneering the world's first at-home, non-invasive cancer screening test for dogs. The test requires only 2 mL of urine to screen for the four most common treatable canine cancers: melanoma, lymphoma, mast cell tumor, and hemangiosarcoma, with a reported accuracy of 90% (83% true positive and 96% true negative). The business model is direct-to-consumer with options for veterinary professional use, offering affordable pricing to make regular screening accessible. They have served over 200 veterinarians and thousands of dog parents, aiming to provide peace of mind and increase treatment options by enabling early cancer detection in dogs. Oncotect is positioned as a routine preventative care measure, recommended annually or every six months for high-risk breeds.